<DOC>
	<DOCNO>NCT01774786</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , randomize , multicenter , international , parallel arm study evaluate efficacy safety pertuzumab combination trastuzumab , fluoropyrimidine cisplatin first-line treatment participant HER2-positive metastatic gastroesophageal junction ( GEJ ) gastric cancer ( GC ) . Participants randomize receive pertuzumab 840 milligram ( mg ) placebo intravenously every 3 week ( q3w ) combination trastuzumab ( initial dose 8 milligram per kilogram [ mg/kg ] intravenously [ IV ] follow 6 mg/kg IV q3w ) cisplatin fluoropyrimidine ( capecitabine 5-fluorouracil ) first 6 treatment cycle . Participants continue receive pertuzumab placebo trastuzumab disease progression occurrence unacceptable toxicity withdrawal study another reason .</brief_summary>
	<brief_title>A Study Pertuzumab Combination With Trastuzumab Chemotherapy Participants With Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Metastatic Gastroesophageal Junction Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm metastatic adenocarcinoma stomach GEJ Measurable evaluable nonmeasurable disease assess investigator accord RECIST v1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy great equal ( &gt; /= ) 3 month Previous cytotoxic chemotherapy advance ( metastatic ) disease Evidence disease progression document within 6 month completion prior neoadjuvant adjuvant cytotoxic chemotherapy , , radiotherapy GEJ adenocarcinoma Previous treatment HER2directed therapy , time , duration Previous exposure investigational treatment within 30 day first dose study treatment Radiotherapy within 30 day first dose study treatment ( within 2 week give palliation bone metastasis , recovered toxicity ) History evidence brain metastasis Clinically significant active gastrointestinal ( GI ) bleeding ( Grade &gt; /=2 accord National Cancer Institute [ NIC ] Common Terminology Criteria Adverse Events Version 4.0 [ CTCAEv.4.0 ] ) Residual toxicity result previous therapy ( example , hematologic , cardiovascular , neurologic toxicity Grade &gt; /=2 ) . Alopecia permit Other malignancy ( addition gastric cancer [ GC ] ) within 5 year enrollment , except carcinoma situ cervix squamous basal cell carcinoma skin previously treat curative intent Inadequate hematologic , renal liver function Pregnant lactate woman History congestive heart failure New York Heart Association ( NYHA ) criteria Angina pectoris require treatment Myocardial infarction within past 6 month first dose study drug Clinically significant valvular heart disease uncontrollable highrisk cardiac arrhythmia History evidence poorly control hypertension Baseline leave ventricular ejection fraction ( LVEF ) value le ( &lt; ) 55 percent ( % ) Any significant uncontrolled intercurrent systemic illness Positive hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>